228.37 USD
+1.84
0.81%
At close Jul 29, 4:00 PM EDT
After hours
228.37
+0.00
0.00%
1 day
0.81%
5 days
1.25%
1 month
-4.93%
3 months
1.93%
6 months
3.67%
Year to date
12.80%
1 year
-3.36%
5 years
41.20%
10 years
232.85%
 

About: Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Employees: 17,787

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

40% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 68

10% more capital invested

Capital invested by funds: $18.8B [Q4 2024] → $20.7B (+$1.91B) [Q1 2025]

1% more funds holding

Funds holding: 756 [Q4 2024] → 764 (+8) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 278

0.53% more ownership

Funds ownership: 92.86% [Q4 2024] → 93.39% (+0.53%) [Q1 2025]

9% less call options, than puts

Call options by funds: $8.15M | Put options by funds: $8.91M

43% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 4 (-3) [Q1 2025]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$250
9%
upside
Avg. target
$271
19%
upside
High target
$288
26%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Keybanc
Brett Fishbin
26%upside
$288
Overweight
Maintained
22 Jul 2025
Morgan Stanley
Patrick Wood
21%upside
$276
Overweight
Upgraded
15 Jul 2025
Jefferies
David Windley
15%upside
$263
Hold
Initiated
29 May 2025
JMP Securities
David Turkaly
23%upside
$280
Market Outperform
Maintained
16 May 2025
Stephens & Co.
Steven Etoch
9%upside
$250
Overweight
Reiterated
15 May 2025

Financial journalist opinion

Based on 4 articles about STE published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
STERIS to Host a Conference Call for Fiscal 2026 First Quarter Results on August 7, 2025
DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
STERIS to Host a Conference Call for Fiscal 2026 First Quarter Results on August 7, 2025
Negative
Zacks Investment Research
1 week ago
Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Steris (STE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Negative
Zacks Investment Research
2 weeks ago
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
Positive
The Motley Fool
4 weeks ago
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money.
Investing in growth stocks is a proven way to increase your investment portfolio over the long term. By parking available funds, say $5,000, in strong, growing companies, and keeping it there long-term, you are likely to see the value of those investments rise steadily, generating the funds you need to finance your future lifestyle.
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money.
Negative
Zacks Investment Research
1 month ago
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
Positive
Zacks Investment Research
2 months ago
AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
Positive
Zacks Investment Research
2 months ago
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
Neutral
GlobeNewsWire
2 months ago
U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%.
U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report 2025-2030 Featuring STERIS, The Brewer Company, Midmark Corp. (Ritter Midmark), Clinton Industries, UMF Medical and More
Neutral
Zacks Investment Research
2 months ago
Deciphering Steris (STE) International Revenue Trends
Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Deciphering Steris (STE) International Revenue Trends
Positive
Seeking Alpha
2 months ago
Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tailwind for Steris's AST business. Steris's balanced growth in pricing and volume, along with cost initiatives, positions it for continued operating margin improvement.
Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Charts implemented using Lightweight Charts™